Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden

Scandinavian Journal of Public Health

Volumn 39, Issue 1, 2011, Pages 79-87

  Valentine, William J ^a   Aagren, Mark ^b   Haglund, Mattias ^c   Ericsson, Åsa ^d   Gschwend, Manuela H ^e  

^a Ossian Health Economics and Communications   (Switzerland)

^b NOVO NORDISK INC   (United States)

^c NEUROSEARCH A S   (Denmark)

^d Novo Nordisk Scandinavia   (Sweden)

^e IQVIA   (United States)

Author keywords

Cost effectiveness; costs; insulin detemir; NPH insulin; Sweden; type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG COST; ECONOMICS; ETHNOLOGY; EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORTALITY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SWEDEN; TIME;

ADULT; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SWEDEN; TIME FACTORS;

EID: 79952272856     PISSN: 14034948     EISSN: None     Source Type: Journal    
DOI: 10.1177/1403494810379290     Document Type: Article

References (34)

1. Karvonen M., Viik-Kajander M. Incidence of childhood type 1 diabetes worldwide. Diabetes Care 2009;23:1516-1526.
2. Bolin K., Gip C., Mork A.C., Lindgren B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005 - a register-based approach. Diabet Med 2009; 26(9):928-934.
3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
4. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643-2653.
5. Herman W.H., Eastman R.C. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl 3): C19-C24.
6. Triplitt C.L., Reasner C.A., Isley W.L. Pharmacotherapy. Chapter 77. Diabetes mellitus. USA: McGraw-Hill; 2008. pp. 1205-1241.
7. Vague P., Selam J.L., Skeie S., De L.I., Elte J.W., Haahr H., et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26(3):590-6.
8. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., Gall M.A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47(4):622-9.
9. Russell-Jones D., Simpson R., Hylleberg B., Draeger E., Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26(5):724-736.
10. Bartley P.C., Bogoev M., Larsen J., Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25(4):442-9.
11. American Diabetes Association. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27(9):2262-5.
12. Palmer A.J., Roze S., Valentine W.J., Minshall M.E., Foos V., Lurati F.M., et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Med Res Opin 2004; 20(Suppl 1):5-26.
13. Palmer A.J., Roze S., Valentine W., Minshall M., Foos V., Lurati F., et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Med Res Opin 2004;20(Suppl 1):S27-S40.
14. Farnkvist L.M., Lundman B.M. Outcomes of diabetes care: a population-based study. Int J Qual Health Care 2003;15(4):301-7.
15. Eeg-Olofsson K., Cederholm J., Nilsson P.M., Gudbjornsdottir S., Eliasson B. Glycaemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30(3):496-502.
16. Clarke P., Gray A., Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22(4):340-9.
17. Tengs T.O., Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38(6):583-637.
18. Australian Institute of Health and Welfare. Diabetes: Australian facts 2002. Report No.: Diabetes Series No. 3; 2002.
19. Carrington A.L., Mawdsley S.K., Morley M., Kincey J., Boulton A.J. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996;32(1-2):19-25.
20. Currie C.J., Morgan C.L., Poole C.D., Sharplin P., Lammert M., McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22(8):1523-1534.
21. Statistics Sweden. http://www.scbse/templates/print149078asp2008 (accessed 11 January 2006).
22. The Swedish Association of Local Authorities and Regions (SALAR). Svenska Kommunföorbundet och Landstingsfördundet i Samverkan. The Swedish Association of Local Authorities and Regions (SALAR) 2006. http://sas.lf.se/kppprod/rap_vikt_tot_2004.htm (accessed 11 January 2006).
23. Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics 2002;20(Suppl 1):43-53.
24. Ghatnekar O., Persson U., Willis M., Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19(7):767-778.
25. Dental and Pharmaceutical Benefits Agency (TLV). http://www.tlvse/in-english/2008 (accessed 11 January 2006).
26. D’Agostino RB, Russell M.W., Huse D.M., Ellison R.C., Silbershatz H., Wilson P.W., et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139(2 Pt 1):272-281.
27. Stevens R.J., Kothari V., Adler A.I., Stratton I.M., Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci [Lond] 2001;101(6):671-9.
28. Kannel W.B., D’Agostino RB, Silbershatz H., Belanger A.J., Wilson P.W., Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159(11):1197-1204.
29. Hermansen K., Madsbad S., Perrild H., Kristensen A., Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24(2):296-301.
30. Home P., Bartley P., Russell-Jones D., Hanaire-Broutin H., Heeg J.E., Abrams P., et al. Insulin detemir offers improved glycaemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27(5):1081-7.
31. Palmer A.J., Valentine W.J., Ray J.A., Foos V., Lurati F., Smith I., et al. An economic assessment of analogue basalbolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin 2007;23(4):895-901.
32. Palmer A.J., Roze S., Valentine W.J., Smith I., Wittrup-Jensen KU Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20(11):1729-1746.
33. Valentine W.J., Palmer A.J., Nicklasson L., Cobden D., Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract 2006;60(9):1138-1145.
34. Palmer A.J., Lammert M., Hermansen K. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark]. Ugeskr Laeger 2008;170(15):1250-4.